Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Boehringer Ingelheim
Purpose:
Study Design:
Age
18–100
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Male or female patient older than 18 years. Adult patient diagnosed with stage IIIb/IV NSCLC locally advanced or metastatic, with activating mutation(s) of EGFR and who is EGFR-TKI naïve.
Patient for whom a decision of treatment with afatinib monotherapy has been taken in the frame of its marketing authorization.
Out-patient. Patient having given written consent for participation in the study. Patient who is able to participate in the investigator's opinion. Patient affiliated with the French social security.
You may not be if
Patients participating in an interventional clinical study. Patients for whom a participation in an interventional clinical study is foreseen within 3 months following the study inclusion.
Patients participating in a therapeutic education program.